Investing.com - Bicycle Therapeutics (NASDAQ:BCYC) reported on Tuesday first quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Bicycle Therapeutics announced earnings per share of $-0.63 on revenue of $3.77M. Analysts polled by Investing.com anticipated EPS of $-0.6182 on revenue of $5.39M.
Bicycle Therapeutics shares are down 21.96% from the beginning of the year, still down 23.48% from its 52 week high of $62.08 set on November 15, 2021. They are under-performing the Nasdaq which is down 12.1% from the start of the year.
Bicycle Therapeutics follows other major Healthcare sector earnings this month
Bicycle Therapeutics's report follows an earnings matched by Roche Holding ADR on February 3, who reported EPS of $1.29 on revenue of $17.54B, compared to forecasts EPS of $1.29 on revenue of $17.1B.
Pfizer had beat expectations on February 8 with fourth quarter EPS of $1.08 on revenue of $23.84B, compared to forecast for EPS of $0.8742 on revenue of $24.16B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar